U.S. Markets close in 5 hrs 25 mins
  • S&P 500

    4,209.21
    +42.76 (+1.03%)
     
  • Dow 30

    33,774.44
    +484.36 (+1.45%)
     
  • Nasdaq

    14,073.79
    +43.41 (+0.31%)
     
  • Russell 2000

    2,266.72
    +28.97 (+1.29%)
     
  • Crude Oil

    72.93
    +1.29 (+1.80%)
     
  • Gold

    1,777.40
    +8.40 (+0.47%)
     
  • Silver

    25.94
    -0.03 (-0.11%)
     
  • EUR/USD

    1.1915
    +0.0049 (+0.4170%)
     
  • 10-Yr Bond

    1.4820
    +0.0320 (+2.21%)
     
  • Vix

    19.04
    -1.66 (-8.02%)
     
  • GBP/USD

    1.3907
    +0.0098 (+0.7093%)
     
  • USD/JPY

    110.1890
    +0.0390 (+0.0354%)
     
  • BTC-USD

    32,821.31
    -1,375.04 (-4.02%)
     
  • CMC Crypto 200

    800.82
    -49.52 (-5.82%)
     
  • FTSE 100

    7,043.70
    +26.23 (+0.37%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

Invitae (NVTA) Outpaces Stock Market Gains: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

In the latest trading session, Invitae (NVTA) closed at $29.95, marking a +1.66% move from the previous day. This change outpaced the S&P 500's 0.74% gain on the day.

Coming into today, shares of the genetic testing company had lost 23.02% in the past month. In that same time, the Medical sector gained 3.01%, while the S&P 500 gained 3.21%.

On that day, NVTA is projected to report earnings of -$0.71 per share, which would represent year-over-year growth of 7.79%. Meanwhile, our latest consensus estimate is calling for revenue of $109.13 million, up 141.96% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$2.65 per share and revenue of $463.63 million, which would represent changes of +4.68% and +66.47%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for NVTA. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 13.66% lower. NVTA currently has a Zacks Rank of #4 (Sell).

The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 219, putting it in the bottom 14% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Invitae Corporation (NVTA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.